ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Alpelisib

Also written as “BYL719”, “alpelisib” and “BYL719 as film-coated (FC) whole tablets”.

Its studies are mostly in Breast Neoplasms · Squamous Cell Carcinoma of Head and Neck · Neoplasms · Ovarian Neoplasms · Lymphatic Abnormalities, led by 4 companies.

Drug pageAlpelisib: every studyAll 85 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Nov 21, 202237 company-led studies, 11 open or runningNext primary completion: Jan 28, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only3310 open or runningphase 4since Nov 21, 2022Oct 6, 2010Jan 28, 2027phase 3 · NCT05038735
Pfizer20 open or runningphase 2since Oct 30, 2012Oct 6, 2011none ahead
Criteriumits history only11 open or runningphase 2since Dec 27, 2021Dec 27, 2021none ahead
Kura Oncologyits history only10 open or runningphase 2since Jul 27, 2021Jul 27, 2021none ahead

Also a collaborator on its studies: ImmunityBio.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 6, 2011First study: phase 1 study in Advanced and Selected Solid TumorsFirst studyNCT01449058 · 139 enrolled · United States, Australia, France and more
  2. Oct 30, 2012Phase 2 study in Colorectal NeoplasmsNCT01719380 · 156 enrolled · United States, Australia, Belgium and more

TargetBeta

PIK3CA →read by rule
“PI3-kinase p110-alpha subunit inhibitor”ChEMBL 37, by rule

Other programs on PIK3CA

ProgramCompanyFurthest phaseStudies
inavolisibruleHoffmann-La Rochephase 320
tersolisibEli Lillyphase 310
gedatolisibrulePfizerphase 39
PI3K-alpha Inhibitor JS105rulerisen-suzhou-pharma-tech-co-ltdphase 31
serabelisibruleTakedaphase 211
paxalisibrulekazia-therapeutics-limitedphase 24
risovalisibruleHaihe Biopharmaphase 24
zovegalisibrulerelay-therapeutics-incphase 22
Mutant-selective PI3K-alpha H1047X Inhibitor SNV4818rulepikavation-therapeutics-incphase 21
Pan-mutant-selective PI3K-alpha Inhibitor and Degrader ETX-636ruleensem-therapeuticsphase 21
RAS/PI3K-alpha Inhibitor VVD-159642ruleBayerphase 11
PI3Ka H1047R Mutant Selective Inhibitor CGT6297rulecogent-biosciences-incphase 11

Studies

All 2 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01719380Colorectal Neoplasms · United States, Australia, Belgium and more2CompletedOct 31, 2015156
NCT01449058Advanced and Selected Solid Tumors · United States, Australia, France and more1CompletedAug 31, 2016139

How it is read

Names in the registry

  • “Alpelisib”, 18 entries
  • “BYL719”, 13 entries
  • “alpelisib”, 3 entries
  • “BYL719 as film-coated (FC) whole tablets”, 1 entry
  • “BYL719 as dispersible tablets (DT)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.